Investor relations

The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies.

December 12, 2024

VERAXA Biotech and Navigo Proteins Initiate Research Collaboration to Establish Pre-Targeting Strategies for Novel Affilin Radio Conjugates

The agreement brings together Navigo Protein’s Affilin® platform with VERAXA’s proprietary click chemistry platform and conjugation expertise

Upcoming events

View All

Jun 16, 2025

June 19, 2025

BIO International Convention, Boston

View event

Jun 16, 2025

June 19, 2025

BIO International Convention, Boston

View event

May 30, 2025

June 3, 2025

ASCO Annual Meeting 2025

View event

May 30, 2025

June 3, 2025

ASCO Annual Meeting 2025

View event

Jan 13, 2025

January 16, 2025

J.P. Morgan Healthcare Week

View event

Jan 13, 2025

January 16, 2025

J.P. Morgan Healthcare Week

View event

Oct 15, 2024

October 17, 2024

Festival of Biologics 2024, Basel

View event

Oct 15, 2024

October 17, 2024

Festival of Biologics 2024, Basel

View event

Latest scientific publications

View All

October 31, 2023

Remodeling the cellular stress response for enhanced genetic code expansion in mammalian cells

Mikhail E. Sushkin, Christine Koehler & Edward A. Lemke

View post

January 1, 2023

Genetic Code Expansion for Site-Specific Labeling of Antibodies with Radioisotopes

Christine Koehler*, Paul F Sauter* , Benedikt Klasen, Christopher Waldmann, Stefanie Pektor, Nicole Bausbacher, Edward A Lemke , Matthias Miederer

View post

January 1, 2021

Synthesis and Evaluation of Novel Ring-Strained Noncanonical Amino Acids for Residue-Specific Bioorthogonal Reactions in Living Cells.

Reinkemeier CD, Koehler C, Sauter PF, Shymanska NV, Echalier C, Rutkowska A, Will DW, Schultz C, Lemke EA

View post